Home » Algeria

Algeria

Plenary – Thursday afternoon session

Item 9. Contributions by the Commission to the work of the Economic and Social Council, including follow-up to and review and implementation of the 2030 Agenda for Sustainable Development Secretary: As you were saying, Mr. Chair, the ECOSOC coordination session was held in february and we supported the chair of the CND in his presentation …

Read more

Plenary — Wednesday morning session

Item 5. Implementation of the international drug control treaties (continued) (a) Changes in the scope of control of substances Chair: First, Commission will consider recommendations of WHO on 4 substances, namely: (a) Whether or not it wishes to include N-pyrrolidino protonitazene in Schedule I of the 1961 Convention as amended; (b) Whether or not it …

Read more

Item 3. General Debate (Cont.)

Item 3. General Debate (Cont.) Iran. I wish to congratulate you for your election. I wish to thank the executive director for organizing this. The global issue of narcotic drugs is undergoing big issues. We are witnessing the emergence of NPS that have challenged monitoring and controlling systems. In order to have a more effective …

Read more

CND Intersessional – Session 6 – Other Substantial Matters

2024 Thematic Discussions on the Implementation of All International Drug Policy Commitments, Following-up to the 2019 Ministerial Declaration Other Substantial Matters proposed by Member States • Challenges to the identification of new illicit drugs: Discussion on strategies and approaches by laboratories to enhance the capacity of forensic personnel and harnessing technology to improve identification methods …

Read more

CND Intersessional – Session 5 – Legal, Scientific, and Regulatory Challenges in Scheduling Substances

2024 Thematic Discussions on the Implementation of All International Drug Policy Commitments, Following-up to the 2019 Ministerial Declaration Chair: Good Morning. Secretariat: (organizational matters + scheduling 101) Moderator/intro: Mr. Justice Tettey, Chief, Drugs, Laboratory and Scientific Services Branch, UNODC: Good morning, dear colleagues. Thank you for this opportunity to address the question you posed about …

Read more